Subscribe

Core intelligence file · AXSM-01

Axsome Therapeutics

NASDAQ: AXSM · Neuroscience / Psychiatry

Clinaptis stanceCautious
ConvictionMedium
Updated
Sep 9, 2026
Company thesis
Intact
Research
1 connected note
Current read

“Axsome has proved it can build a valuable CNS franchise; AXSM's problem is expectations, not product quality. Auvelity's Alzheimer's disease agitation expansion addresses a strong indication with genuine clinical differentiation, but institutional adoption—particularly across long-term care—is likely to develop more slowly than the valuation assumes. MDD growth can normalize after an exceptional launch without breaking the company thesis. The security thesis turns on whether four to six months of ADA evidence can support a material second growth leg and close the gap between the current equity value and our $150–170 anchor.”

The maintained investment case

Auvelity has established a real and rapidly growing MDD franchise, and its 2026 approval in agitation associated with Alzheimer's dementia creates a potentially larger second indication with a differentiated non-antipsychotic profile. The opportunity is real, but the current security case requires multiple optimistic assumptions: continued MDD durability, a strong ADA launch and useful late-stage pipeline contribution.

  1. The company thesis remains Intact while the security thesis stays Conditional until four to six months of evidence clarify whether ADA is a genuinely incremental growth leg.

Where the market may differ

The market often frames the debate around the large ADA population and Auvelity's differentiated label. Clinaptis instead focuses on conversion velocity.

  1. Institutional prescribing across geriatrics, memory care and long-term care can be slower than theoretical demand suggests, and current reporting blends MDD and ADA. The decisive evidence is indication-level or credible proxy data showing incremental ADA prescriptions while MDD remains durable.
What matters most
  1. 01

    ADA adoption velocity rather than theoretical TAM: the stock will resolve on the shape and durability of the prescription curve.

  2. 02

    MDD durability as the writer mix broadens beyond the specialist cohort that built the launch.

  3. 03

    The de-rating improves the setup, but AXSM remains above the working $150–170 anchor and still requires meaningful ADA contribution.

  4. 04

    Solriamfetol, AXS-12, AXS-14 and smoking-cessation development must become real diversification rather than undifferentiated pipeline value.

  5. 05

    Long-duration operating leverage matters to FY2028–33 value but is secondary to near-term ADA conversion.